www.koreabiomed.com
Open in
urlscan Pro
49.50.169.119
Public Scan
URL:
http://www.koreabiomed.com/news/articleView.html?idxno=12430
Submission: On December 23 via api from US — Scanned from DE
Submission: On December 23 via api from US — Scanned from DE
Form analysis 3 forms found in the DOM
Name: head-search — POST /news/articleList.html
<form name="head-search" class="clearfix" method="post" action="/news/articleList.html">
<input type="hidden" name="sc_area" value="A">
<input type="hidden" name="view_type" value="sm">
<label class="show-for-sr" for="search">기사검색</label>
<input type="text" name="sc_word" id="search" onkeydown="if(event.keyCode==13){if(this.form.sc_word.value != ''){this.form.submit();}else{alert('검색어를 입력해주세요');return false;}}" placeholder="검색어를 입력해주세요" title="검색어">
<button type="button" title="검색" onclick="if(this.form.sc_word.value != ''){this.form.submit();}else{alert('검색어를 입력해주세요');this.form.sc_word.focus();return false;}"><span class="show-for-sr">검색</span></button>
</form>Name: replyForm — POST articleReply.php
<form id="reply-form" name="replyForm" method="post" action="articleReply.php">
<input id="reply-insert-article-idxno" name="parent_idxno" type="hidden" value="12430">
<input id="reply-insert-user-id" name="user_id" type="hidden" value="">
<input id="reply-insert-mode" name="mode" type="hidden" value="input">
<input id="g-recaptcha-response" name="g-recaptcha-response" type="hidden" value="">
<input id="reply-page" name="reply_page" type="hidden" placeholder="페이징" value="1">
<input id="reply-all" name="replyAll" type="hidden" placeholder="전체보기" value="">
<input id="reply-sc-order-by" name="reply_sc_order_by" type="hidden" placeholder="댓글정렬" value="I">
<header class="cmt-header">
<div id="login-member" class="login-member"><i class="icon-profile"></i> </div>
<div class="reply-name" style="display:none">
<h5 class="show-for-sr">비회원 로그인</h5>
<div class="item reply-write-name">
<label for="reply-insert-name" class="show-for-sr">이름</label>
<input type="text" name="name" id="reply-insert-name" class="small" title="이름" placeholder="이름" value="">
</div>
<div class="item reply-write-password">
<label for="reply-insert-password" class="show-for-sr">비밀번호</label>
<input type="password" name="password" id="reply-insert-password" class="small" title="비밀번호" placeholder="비밀번호" value="">
</div>
</div>
</header>
<!-- 댓글입력 //-->
<section class="cmt-container">
<label for="content" class="show-for-sr">댓글 내용입력</label>
<textarea name="content" id="content" title="댓글 내용입력" class="reply-content required" placeholder="권리침해, 욕설 및 특정 대상을 비하하는 내용을 게시할 경우 이용약관 및 관련법률에 의해 제해될 수 있습니다. 공공기기에서는 사용 후 로그아웃 해주세요."></textarea>
<div class="cmt-footer">
<span class="reply-textnum"><strong id="reply-cur-text">0</strong> / 400</span>
<button type="submit" class="button user-bg standard"><i class="icon-comment-o"></i> 등록</button>
</div>
</section>
<!--// 댓글입력 -->
</form>Name: replyForm — POST articleReplyDelete.php
<form id="reply-delete-form" name="replyForm" method="post" action="articleReplyDelete.php">
<input id="reply-delete-mode" name="mode" type="hidden" placeholder="삭제모드" value="">
<input id="reply-delete-idxno" name="idxno" type="hidden" placeholder="삭제번호" value="">
<input id="reply-delete-reply-parent-idxno" name="reply_parent_idxno" type="hidden" placeholder="삭제부모번호" value="">
<input id="reply-delete-parent-idxno" name="parent_idxno" type="hidden" placeholder="기사번호" value="12430">
<input id="reply-delete-reply-page" name="reply_page" type="hidden" placeholder="페이징" value="1">
<input id="reply-delete-reply-all" name="replyAll" type="hidden" placeholder="전체보기" value="">
<input id="reply-delete-reply-sc-order-by" name="reply_sc_order_by" type="hidden" placeholder="댓글정렬" value="I">
<!-- 비밀번호 //-->
<fieldset id="delete-password-field" class="row expanded small-collapse medium-uncollapse">
<div class="medium-3 columns">
<label for="password" class="medium-middle"><strong class="key-point">비밀번호</strong></label>
</div>
<div class="medium-9 columns">
<input type="password" name="password" id="password" title="비밀번호" maxlength="20" placeholder="비밀번호 입력" class="required">
</div>
</fieldset>
<!--// 비밀번호 -->
<footer class="clearfix text-center">
<button class="button"><i class="icon-trash-o"></i> 삭제</button>
</footer>
</form>Text Content
주요서비스 바로가기 본문 바로가기 매체정보 바로가기 로그인 바로가기 기사검색 바로가기 전체서비스 바로가기 상단영역 UPDATE : 2021-12-23 18:01 (Thu) Home Log in Join 전체메뉴 기사검색 검색 본문영역 이전 기사보기 다음 기사보기 Geninus sets offering price at ₩20,000 for IPO in November 바로가기 복사하기 본문 글씨 줄이기 본문 글씨 키우기 스크롤 이동 상태바 현재위치 * HOME * Bio GENINUS SETS OFFERING PRICE AT ₩20,000 FOR IPO IN NOVEMBER * 기자명 Kim Chan-hyuk * Published 2021.10.27 11:55 바로가기 복사하기 본문 글씨 줄이기 본문 글씨 키우기 SNS 기사보내기 페이스북(으)로 기사보내기 트위터(으)로 기사보내기 카카오스토리(으)로 기사보내기 URL복사(으)로 기사보내기 이메일(으)로 기사보내기 다른 공유 찾기 기사스크랩하기 Geninus said it set its public offering price at 20,000 won ($17.14) for the initial public offering on the Kosdaq market in November. In a public filing on Tuesday, the biotech company said that the two-day book building on Thursday and Friday showed that the competition rate of institutional investors was one in 66. Geninus set its public offering price at 20,000 won before going public on Nov. 9. The company plans to offer 2 million shares worth 40 billion won, and the market capitalization is expected to mark 217.4 billion won immediately after the IPO. “I would like to thank the institutional investors who took great interest in Geninus and participated in the book building,” said Park Yang-woong, CEO of Geninus. “Through the listing on Kosdaq, the company will enhance existing business with active R&D and continuous facility investment and lay the ground for new business and entry into the global market.” He added that the company aims to lead the genome analysis market and become a new drug platform developer through collaborations with hospitals and other drugmakers. Geninus said it would spend the funds raised through IPO on R&D for cancer genome diagnosis and single-cell analysis. Also, the company plans to hire talents to make a new drug development platform. The public offering for retail investors will take place on Wednesday and Thursday this week, and 25 percent of all new shares, or 500,000 shares, will be offered. Geninus plans to go public on Nov. 9, and Daishin Securities is the lead underwriter. Kim Chan-hyuk kch@docdocdoc.co.kr See Other Articles Copyright © KBR Unauthorized reproduction, redistribution prohibited News That You Haven't Seen Government may not approve Novavax’s Covid-19 vaccine within this year Korean pharma uses long-term strategy for Covid-19 drugs HLB verifies efficacy of Nanogen's Covid-19 vaccine in Vietnam ‘Digital technology can improve access to mental healthcare’ Merck's oral Covid-19 treatment raises interest in related Korean stocks Novartis reduces CAR-T manufacturing time to 2 days GE Healthcare, Medical AI to develop, commercialize AI-based electrocardiogram reading tech Government may not approve Novavax’s Covid-19 vaccine within this year COMMENTS 0 댓글 접기 Available after login. 댓글 내용입력 0 / 400 비회원 로그인 이름 비밀번호 댓글 내용입력 0 / 400 등록 Important News Korea joins global race to secure oral Covid-19 treatments inno.N licenses out gastroesophageal reflux therapy to US Vaccine developers demand state support for Omicron vaccine MDoc launches home care platform for dialysis patients CHA hospital conducts world’s 1st POEM surgery on infant with ataxia AMC develops method to monitor transplanted stem cells in real-time Recent News Korea joins global race to secure oral Covid-19 treatments inno.N licenses out gastroesophageal reflux therapy to US Vaccine developers demand state support for Omicron vaccine MDoc launches home care platform for dialysis patients CHA hospital conducts world’s 1st POEM surgery on infant with ataxia Photo News Korea joins global race to secure oral Covid-19 treatments inno.N licenses out gastroesophageal reflux therapy to US Vaccine developers demand state support for Omicron vaccine MDoc launches home care platform for dialysis patients Most Viewed 1 Government may not approve Novavax’s Covid-19 vaccine within this year 2 Korean pharma uses long-term strategy for Covid-19 drugs 3 HLB verifies efficacy of Nanogen's Covid-19 vaccine in Vietnam 4 ‘Digital technology can improve access to mental healthcare’ 5 Merck's oral Covid-19 treatment raises interest in related Korean stocks 6 Novartis reduces CAR-T manufacturing time to 2 days 7 GE Healthcare, Medical AI to develop, commercialize AI-based electrocardiogram reading tech 8 POSTECH team develops testing method to detect Omicron variant 하단영역 Important EuBiologics agrees to sell Covid-19 vaccine in Saudi Arabia Korea joins global race to secure oral Covid-19 treatments inno.N licenses out gastroesophageal reflux therapy to US Vaccine developers demand state support for Omicron vaccine MDoc launches home care platform for dialysis patients CHA hospital conducts world’s 1st POEM surgery on infant with ataxia AMC develops method to monitor transplanted stem cells in real-time Government to charge drugmakers for re-prescription costs incurred by impurity Korea reviewing to clear Pfizer’s Covid-19 pill More than 6 in 10 elderly Koreans fully vaccinated, boosted Amgen’s psoriasis drug Otezla wins expanded indication in US LG Chem ends recruiting participants for phase 1 study of NASH treatment EuBiologics agrees to sell Covid-19 vaccine in Saudi Arabia Korea joins global race to secure oral Covid-19 treatments Latest Cause of endoscopic vacuum therapy failure confirmed for 1st time St. Mary’s Hospital develops AI-based glaucoma vision test result extraction system JW Pharma's Danish partner to start global P2b trial of atopic dermatitis treatment SNUH team finds risks of deep spinal infection after epidural injection POSTECH team develops testing method to detect Omicron variant Acromegaly treatment’s supply suspended as Novartis hands over sales rights Prestige Biopharma's Herceptin biosimilar to land in Latin America, Southeast Asia Samsung Bioepis presents more P3 study data on trastuzumab biosimilar Celltrion scores conditional approval for Covid-19 treatment in Australia Bertis and NCCRI to co-develop proteomics-based cancer diagnosis and treatment Hanmi's US partner submits new drug application for poziotinib CHA Hospital finds method inhibiting head and neck cancer cell growth Cause of endoscopic vacuum therapy failure confirmed for 1st time St. Mary’s Hospital develops AI-based glaucoma vision test result extraction system * facebook * twitter * rss 하단메뉴 About KBR Tip off Advertising Site Feedback Privacy Policy Adolescent Protection Policy E-mail address privacy 매체정보 * The Korean Doctors’ Weekly Co., Ltd * 76-1, Dongmak-ro, Mapo-gu, Seoul, Korea * Tel : 82-2-2646-0852 * Fax : 82-2-703-3916 * Title : KBR * Online newspaper registration number : Seoul 아 04285 * Date of registration : December 19, 2016 * Publishing date : February 22, 2017 * Publisher-Editor : Yang Kyung-cheol * Executive Editor : Choi Sung-jin * Chief Executive Officer : Yang Kyung-cheol * Copyright © KBR. All rights reserved. 위로 전체메뉴 * All * Hospital * Pharma * Bio * 전체 * Korea‘s Bio Industry * Device/ICT * Policy * People * Life science * Special * 전체 * Innovation for Survival * Korea’s medical culture series * Korea’s New Candidate Drug Watch List * Special Series in Celebration of KBR's 1st Anniversary * Interview with foreign envoys * Special Series in Celebration of KBR’s 2nd Anniversary * Interview with global pharma * Special Series in Celebration of KBR’s 3rd Anniversary * Special Series in Celebration of KBR’s 4th Anniversary * ASCO 2020 Highlights * SPECIAL SERIES IN CELEBRATION OF KBR’S 5TH ANNIVERSARY * KBR Covering RSNA 2021 * Opinion * 전체 * Reporter’s Notebook * Journalist’s Column * Congratulatory Remarks * Sponsored 전체메뉴닫기 이 기사를 공유합니다 페이스북(으)로 기사보내기 트위터(으)로 기사보내기 카카오스토리(으)로 기사보내기 URL복사(으)로 기사보내기 닫기 댓글삭제 삭제한 댓글은 다시 복구할 수 없습니다. 그래도 삭제하시겠습니까? 비밀번호 삭제 닫기 댓글쓰기 계정을 선택하시면 로그인·계정인증을 통해 댓글을 남기실 수 있습니다. 회원 로그인 비회원 글쓰기 이름 비밀번호 자동등록방지 확인 취소 로그인 옵션 창닫기 인쇄 URL주소 본문글씨 줄이기 본문글씨 키우기 인쇄 URL주소 본문글씨 줄이기 본문글씨 키우기 페이스북 트위터 카카오스토리 URL복사 이메일 다른 공유 기사스크랩 페이스북 트위터 카카오스토리 URL복사